Alzheimer's Disease Trial, Recruiting NCT05661084 Sponsor: Hebrew SeniorLife Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT05661084
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For participants:

  • You are willing and able to give your consent to join the study after it has been fully explained to you.
  • You are able and willing to follow all the requirements of the study.
  • You have signed a consent form agreeing to take part.
  • You are able to read, write, and communicate in English.

For caregivers/administrators (the person who helps deliver the treatment):

  • You are at least 18 years old.
  • You are able to read, write, and communicate in English.
  • You feel comfortable using a computer and are willing to learn how to deliver the brain stimulation treatment (called tES) to the participant.
  • You are available on weekdays throughout the study to deliver the treatment to the participant.

Who may not be able to join:

For participants:

  • You have a major mental health condition such as severe depression, schizophrenia, or psychosis.
  • You have blindness or another disability that would prevent you from completing the study tasks.
  • You have certain health factors that make the brain stimulation treatment (tES) unsafe for you, such as having had a seizure in the past two years, taking medications that affect the brain, or having certain implanted medical devices (such as a deep brain stimulator, medication pump, or cochlear implant).
  • You have an active skin condition, such as eczema, on your scalp.
  • You score 18 or below on a standard memory and thinking test called the Montreal Cognitive Assessment (MoCA) during an in-person screening visit.
  • You are unable to show a clear understanding of what the study involves after reviewing the consent form (confirm with trial site).

For caregivers/administrators:

  • You show signs of mild memory or thinking difficulties, based on a score of 26 or below on the MoCA test during an in-person screening visit.
  • You are unable to show a clear understanding of what the study involves after reviewing the consent form (confirm with trial site).
  • You have poor eyesight, severe arthritis in your hands, pain, a physical deformity, or any other condition that would make it difficult for you to deliver the brain stimulation treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alvaro Pascual-Leone, MD; PhD, Hebrew SeniorLife

Phone: 617-971-5416

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hebrew SeniorLife
Registry
ClinicalTrials.gov
Start date
24 January 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Rey Auditory Verbal Learning Test (RAVLT) Total Recall; Change in Dual Task Cost to Gait

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov